Paper

Acta Haematol 1993;89(suppl 1):33

Closing Remarks

J.M.

John M.

Goldman

London

The speakers have very eloquently conveyed the message of this satellite symposium. We have in the last decade seen the birth and development of a completely new approach to treating patients with hematological malignancies – an approach that exploits what we know of the basic lesion in leukemia and lymphoma and tries to correct the cellular or molecular defect by recruiting normal or near-normal mechanisms. The era of cytotoxic drugs is not finished, rather we may hope that the combined use of cytotoxic drugs and biological molecules, some of which we have heard about and others of which are yet undiscovered, will increase the chance of complete remission and cure for our patients. I see no reason why this should not be.